TriSalus Life Sciences Acquires Dynavax’s SD-101 Oncology Program in Purchase Agreement for up to $250 million in Milestone Payments plus Royalties on Future Net Sales

NEXT STORY
Cytovia Therapeutics Acquires Worldwide Rights to CytoImmune Therapeutics’ First-In-Class EGFR Dual-targeting CAR for NK Cell Treatment of Glioblastoma & Other Solid Tumors
PREV STORY
Graybug Vision Appoints Leading Ophthalmologists and Retinal Experts to Join Its Scientific Advisory Board
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine Present New Clinical Data on GD2 CAR-NKT Cells in Neuroblastoma at ASGCT Annual Meeting

author_avatar
NASDAQ Market News

Apellis to Present New Data Reinforcing EMPAVELI™ (pegcetacoplan) Efficacy and Safety in Patients with PNH at the 2021 ASH Annual Meeting

author_avatar
NASDAQ Market News

INC Research Launches Catalyst Program to Strengthen Collaboration With Clinical Research Sites, Enhance Delivery to Customers

RALEIGH, N.C., Feb. 17, 2016 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a ...

author_avatar
NASDAQ Market News